
Shire reassures Baxalta acquisition on track in the aftermath of Pfizer-Allergan breakup
pharmafile | April 7, 2016 | News story | Business Services, Sales and Marketing |ย ย AbbVie, Allergan, Baxalta, Deals, Financial, Merger & Acquisition, Pfizer, Shireย
Ireland-headquartered Shire Plc (LSE: SHP) has reassured its $32-billion merger deal with US-based Baxlata (NYSE: BXLT) remains on track in the backdrop of new US Treasury Department rules announced Monday.
Shire said it expects to complete the transaction by mid-2016. The Shire-Baxalta merger is targeted at creating a biotechnology firm focused on rare diseases, the company said in a statement.
In January, Baxalta agreed a takeover by Shire following months of wooing.
US regulators have implemented new regulations in a bid to control tax inversions that has led to the termination of $160 billion Pfizer (NYSE: PFE) deal with Dublin-based Allergan (NYSE: AGN).
However, this isnโt the first time government action in the US has derailed a pharma transaction. In 2014, a similar regulatory implementation led to Abbvie (NYSE: ABBV) calling off its $52 billion takeover of Shire. Previously, Shire and AbbVie agreed to terminate a merger accord following previous changes introduced in September to US tax rules.
Anjali Shukla
Related Content
NICE recommends Pfizerโs new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21stย May 2025ย โย Pfizer Ltd announced today that the National Institute for Health and Care …

Genmab to submit FDA application for lymphoma therapy
Global biotechnology company Genmab plans to submit a supplemental Biologics License Application (sBLA) to the …

The National Institute for Health and Care Excellence announce technology appraisal guidance recommending risankizumab for adult patients with moderate to severe ulcerative colitis
The National Institute for Health and Care Excellence (NICE) have recommended adult patients in England …






